Strategic partnerships Strengthening ties with major cancer centers and research institutions is a clear growth path. Notable recent collaborations with Centre Léon Bérard, Stanford Medicine, and potential integration opportunities with Mevion and GE HealthCare indicate receptiveness to upright positioning technology in advanced radiotherapy workflows.

Proton therapy potential The ongoing development and integration of upright positioning with compact proton systems (Mevion MEVION S250-FIT and Stanford Medicine integration) suggests a sizable addressable market in proton therapy where infrastructure and patient experience are critical.

Regulatory readiness Products are not yet commercially available pending FDA approval and CE marking. This implies a multi-stage engagement plan prioritizing regulatory milestones, clinical evidence generation, and early payer conversations to accelerate market entry.

Clinical evidence focus Active research collaborations and pilot studies on upright positioning, particularly for pelvic tumors, provide compelling case studies. Leverage these findings to build credibility with hospital procurement teams and radiotherapy program directors.

Expansion signals Significant fundraising and press on Series D funding, along with international partnerships and industry conference presence, signal readiness to scale operations, support global pilots, and pursue large health system deployments.